SLF1: A Non-Coding RNA Molecule as A Potential Drug Target (G84250)

Target Name: SLF1

NCBI ID: G84250

SLF1

SLF1: A Non-Coding RNA Molecule as A Potential Drug Target

SLF1 (Smc5/6 localization factor 1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique function as a localization factor has led to a growing interest in its role in the regulation of cellular processes, including cell adhesion, migration, and invasion.

SLF1 is a member of the Smc family, which includes several similar non-coding RNAs, including Smc1, Smc2, Smc3, Smc4, and Smc6. These non-coding RNAs play a crucial role in maintaining the stability and integrity of chromosome structure, as well as regulating various cellular processes. The Smc family is also known as the nucleosome-remodeling complex, which is involved in the regulation of DNA replication, repair, and quality cell cycle progression.

SLF1 is expressed in various tissues and cells, including muscle, liver, brain, and cancer cells. It has been shown to localize to specific regions of the genome, including the heterochromatin regions of the genome. SLF1 has been shown to play a role in the regulation of gene expression, by binding to specific DNA sequences and affecting the translation of RNA into protein.

One of the most significant functions of SLF1 is its role in cell adhesion. SLF1 has been shown to localize to the adhesion front, which is the region of the cell that forms the interface between the cell and the surrounding environment. regulate the formation of tight junctions, which are a type of cell-cell adhesion, as well as the maintenance of cell-cell contact.

SLF1 has also been shown to play a role in the regulation of cell migration.SLF1 has been shown to localize to the center of the cell, where it is involved in the regulation of the actin cytoskeleton and the decision of cell division. This localization is also known as the \"cell-center problem,\" which is a challenge in understanding the mechanisms of cell migration and division.

SLF1 has also been shown to play a role in the regulation of neurodegenerative diseases. SLF1 has been shown to localize to the neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This localization is thought to be due to the fact that SLF1 is involved in the regulation of the production of neurotransmitters, which are involved in the regulation of neural function.

SLF1 has also been shown to play a role in the regulation of autoimmune disorders. SLF1 has been shown to localize to the autoimmune disorders, including rheumatoid arthritis, and multiple sclerosis. This localization is thought to be due to the fact that SLF1 is involved in the regulation of the immune response, by regulating the production of T cells and B cells.

In conclusion, SLF1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique function as a localization factor has led to a growing interest in its role in the regulation of cellular processes, including cell adhesion, migration, and invasion. Further research is needed to fully understand the role of SLF1 in these cellular processes and its potential as a drug target and biomarker.

Protein Name: SMC5-SMC6 Complex Localization Factor 1

Functions: Plays a role in the DNA damage response (DDR) pathway by regulating postreplication repair of UV-damaged DNA and genomic stability maintenance (PubMed:25931565). The SLF1-SLF2 complex acts to link RAD18 with the SMC5-SMC6 complex at replication-coupled interstrand cross-links (ICL) and DNA double-strand breaks (DSBs) sites on chromatin during DNA repair in response to stalled replication forks (PubMed:25931565). Promotes the recruitment of SLF2 and the SMC5-SMC6 complex to DNA lesions (PubMed:25931565)

The "SLF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets